Press releases
Loading...
Message from the CEO
”SynAct is in a fortunate position now as the company has two development tracks, across both autoimmune and infection-driven inflammation, for resomelagon.”
Latest news and press releases
Loading...
Loading...
Subscribe to press releases
and reports
Loading...